

Yanan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2551104/publications.pdf>

Version: 2024-02-01

64
papers

1,823
citations

331538

21
h-index

276775

41
g-index

64
all docs

64
docs citations

64
times ranked

3489
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. <i>Cardiovascular Research</i> , 2022, 118, 489-502.	1.8	34
2	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. <i>Circulation</i> , 2021, 143, 921-934.	1.6	55
3	Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE ⁻³ -Leiden.CETP mice. <i>Journal of Lipid Research</i> , 2021, 62, 100070.	2.0	9
4	Hepatic Scavenger Receptor Class B Type 1 Knockdown Reduces Atherosclerosis and Enhances the Antiatherosclerotic Effect of Brown Fat Activation in APOE ^{*3} -Leiden.CETP Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1474-1486.	1.1	6
5	A hierarchical dynamic model used for investigating feed efficiency and its relationship with hepatic gene expression in APOE ^{*3} -Leiden.CETP mice. <i>Physiological Reports</i> , 2021, 9, e14832.	0.7	2
6	Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE ^{*3} -Leiden.CETP mice. <i>Pharmacological Research</i> , 2021, 167, 105524.	3.1	9
7	Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development. <i>Cardiovascular Research</i> , 2020, 116, 1710-1720.	1.8	22
8	Continuous Light Does Not Affect Atherosclerosis in APOE ^{*3} -Leiden.CETP Mice. <i>Journal of Biological Rhythms</i> , 2020, 35, 598-611.	1.4	4
9	Î ²⁴ -Dehydrocholesterol reductase (DHCR24): A novel target for the treatment of nash. <i>Atherosclerosis</i> , 2020, 315, e11.	0.4	0
10	A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 334-343.	3.1	22
11	Electrical Neurostimulation Promotes Brown Adipose Tissue Thermogenesis. <i>Frontiers in Endocrinology</i> , 2020, 11, 567545.	1.5	4
12	Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. <i>Scientific Reports</i> , 2019, 9, 9996.	1.6	5
13	Inhibition of Î ²⁴ -dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20623-20634.	3.3	38
14	The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1. <i>Diabetes</i> , 2019, 68, 2223-2234.	0.3	5
15	Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic MicroRNAs Among Extracellular Vesicles, HDL, and Ago-2. <i>Diabetes</i> , 2019, 68, 2287-2300.	0.3	37
16	Computational modelling of energy balance in individuals with Metabolic Syndrome. <i>BMC Systems Biology</i> , 2019, 13, 24.	3.0	6
17	Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. <i>European Journal of Human Genetics</i> , 2019, 27, 422-431.	1.4	30
18	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 854-862.	2.5	62

#	ARTICLE	IF	CITATIONS
19	Lipopolysaccharide Lowers Cholesteryl Ester Transfer Protein by Activating F4/80 ⁺ Clec4f ⁺ Vsig4 ⁺ Ly6C ^{hi} Kupffer Cell Subsets. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	27
20	Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. <i>Gut</i> , 2018, 67, 1269-1279.	6.1	401
21	Circulating cetp is not related to the hepatic triglyceride content: Lessons from a liraglutide intervention trial and a population-based cohort. <i>Atherosclerosis</i> , 2018, 275, e60.	0.4	0
22	Bile acid sequestrant colesevelam enhances beneficial effects of brown fat activation on cholesterol metabolism in APOE ³ -Leiden.CETP mice. <i>Atherosclerosis</i> , 2018, 275, e23.	0.4	0
23	Butyrate via the gut-brain neural circuit reduces appetite and activates brown adipose tissue. <i>Atherosclerosis</i> , 2018, 275, e15-e16.	0.4	4
24	Genetically-determined CETP concentration decreases large HDL and increases small VLDL without affecting LDL. <i>Atherosclerosis</i> , 2018, 275, e25.	0.4	0
25	Impact of rural-urban environment on metabolic profile and response to a 5-day high-fat diet. <i>Scientific Reports</i> , 2018, 8, 8149.	1.6	11
26	CETP (Cholesteryl Ester Transfer Protein) Concentration. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002034.	1.6	44
27	FXR activation normalizes dyslipidemia and alleviates obesity in western-type diet ^{fed} APOE ³ -Leiden.CETP transgenic mice. <i>Atherosclerosis</i> , 2018, 275, e10.	0.4	0
28	Metabolic liver inflammation in obesity does not robustly decrease hepatic and circulating CETP. <i>Atherosclerosis</i> , 2018, 275, 149-155.	0.4	5
29	In vivo and in silico dynamics of the development of Metabolic Syndrome. <i>PLoS Computational Biology</i> , 2018, 14, e1006145.	1.5	12
30	LPS reduces hepatic CETP expression by mature resident macrophages. <i>Atherosclerosis</i> , 2017, 263, e8-e9.	0.4	0
31	Statin treatment potentiates the lipid-lowering and anti-atherogenic effect of bat activation by accelerating lipoprotein remnant clearance. <i>Atherosclerosis</i> , 2017, 263, e212.	0.4	0
32	Male apoE ³ -Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men. <i>Physiological Reports</i> , 2017, 5, e13376.	0.7	19
33	Butyrate via the gut-brain neuronal circuit reduces appetite and activates brown adipose tissue. <i>Atherosclerosis</i> , 2017, 263, e85.	0.4	2
34	Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. <i>Atherosclerosis</i> , 2017, 267, 116-126.	0.4	23
35	Butyrate via the gut-brain circuit reduces appetite and activates brown adipose tissue. <i>Atherosclerosis</i> , 2016, 252, e250.	0.4	0
36	Serum CETP concentration is not associated with measures of body fat: The NEO study. <i>Atherosclerosis</i> , 2016, 246, 267-273.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. <i>Hepatology</i> , 2015, 62, 1710-1722.	3.6	60
38	Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. <i>Clinical Science</i> , 2015, 128, 143-151.	1.8	34
39	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. <i>Journal of Lipid Research</i> , 2015, 56, 2085-2093.	2.0	27
40	Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. <i>Diabetologia</i> , 2015, 58, 2637-2646.	2.9	100
41	Differential Complement Activation Pathways Promote C3b Deposition on Native and Acetylated LDL thereby Inducing Lipoprotein Binding to the Complement Receptor 1. <i>Journal of Biological Chemistry</i> , 2014, 289, 35421-35430.	1.6	16
42	Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. <i>British Journal of Pharmacology</i> , 2014, 171, 723-734.	2.7	95
43	Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1423-1430.	1.9	49
44	Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1529-1537.	1.1	79
45	PS13 - 7. Plasma cholesteryl ester transfer protein: a biomarker for hepatic macrophages. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013, 11, 195-195.	0.0	0
46	Acute Central Neuropeptide Y Administration Increases Food Intake but Does Not Affect Hepatic Very Low-Density Lipoprotein (Vldl) Production in Mice. <i>PLoS ONE</i> , 2013, 8, e55217.	1.1	7
47	BMP7 Activates Brown Adipose Tissue and Reduces Diet-Induced Obesity Only at Subthermoneutrality. <i>PLoS ONE</i> , 2013, 8, e74083.	1.1	82
48	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. <i>PLoS ONE</i> , 2013, 8, e63882.	1.1	14
49	PS1 - 5. The GLP-1 receptor agonist exendin-4 reduces atherosclerosis development and NASH in APOE*3.Leiden.CETP mice. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 102-102.	0.0	0
50	PS19 - 90. BMP-7 reduces high fat diet-induced adiposity in mice by activating brown adipose tissue in a sympathetic-dependent way: Implications for obesity. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 163-163.	0.0	0
51	Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. <i>Biochemical Pharmacology</i> , 2012, 84, 821-829.	2.0	21
52	GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. <i>PLoS ONE</i> , 2012, 7, e49152.	1.1	71
53	5 THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENDIN-4 INHIBITS VLDL BIOSYNTHESIS AND SECRETION IN APOE*3-LEIDEN MICE. <i>Atherosclerosis Supplements</i> , 2011, 12, 2.	1.2	0
54	172 NIACIN, ATORVASTATIN AND FENOFIBRATE DECREASE PLASMA CETP BY REDUCTION OF THE HEPATIC MACROPHAGE CONTENT IN APOE*3-LEIDEN.CETP MICE. <i>Atherosclerosis Supplements</i> , 2011, 12, 38.	1.2	0

#	ARTICLE	IF	CITATIONS
55	The aminoterminal 1-185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL-like particles in apoA-I deficient mice. <i>Atherosclerosis</i> , 2011, 219, 116-123.	0.4	2
56	PS16 - 81. Chronic niacin treatment of ApoE*3Leiden-CETP mice results in impaired insulin mediated repression of lipolysis in isolated adipocytes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2011, 9, 146-146.	0.0	0
57	PS16 - 82. GLP-1 receptor agonism inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high fat diet-fed APOE*3-Leiden mice. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2011, 9, 147-147.	0.0	0
58	Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Plasma CETP and Increases Apolipoprotein AI Levels Without Improving the Cholesterol Efflux Properties of HDL. <i>Diabetes Care</i> , 2011, 34, 2576-2580.	4.3	33
59	CETP expression reverses the reconstituted HDL-induced increase in VLDL. <i>Journal of Lipid Research</i> , 2011, 52, 1533-1541.	2.0	7
60	Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1625-1628.	4.3	20
61	Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. <i>Atherosclerosis</i> , 2010, 210, 381-387.	0.4	5
62	Enhanced atherothrombotic formation after oxidative injury by FeCl ₃ to the common carotid artery in severe combined hyperlipidemic mice. <i>Biochemical and Biophysical Research Communications</i> , 2009, 385, 563-569.	1.0	7
63	Combined Deletion of Macrophage ABCA1 and ABCG1 Leads to Massive Lipid Accumulation in Tissue Macrophages and Distinct Atherosclerosis at Relatively Low Plasma Cholesterol Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 258-264.	1.1	178
64	Overexpression of apolipoprotein AV in the liver reduces plasma triglyceride and cholesterol but not HDL in ApoE deficient mice. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 14-18.	1.0	9